{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"ForeignBrandName","name":"Kevadon"},{"type":"ObsoleteName","name":"Synovir"},{"type":"USBrandName","name":"Thalomid"},{"type":"ChemicalStructureName","name":"2,6-dioxo-3-phthalimidopiperidine"},{"type":"ChemicalStructureName","name":"2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione"},{"type":"ChemicalStructureName","name":"3-phthalimidoglutarimide"},{"type":"Synonym","name":"alpha-phthalimidoglutarimide"},{"type":"ForeignBrandName","name":"Contergan"},{"type":"ForeignBrandName","name":"Distaval"},{"type":"ChemicalStructureName","name":"N-(2,6-dioxo-3-piperidyl)phthalimide"},{"type":"Synonym","name":"N-phthaloylglutamimide"},{"type":"Synonym","name":"N-phthalylglutamic acid imide"},{"type":"ForeignBrandName","name":"Neurosedyn"},{"type":"ForeignBrandName","name":"Pantosediv"},{"type":"ObsoleteName","name":"Sedalis"},{"type":"ForeignBrandName","name":"Sedoval K-17"},{"type":"ForeignBrandName","name":"Sedoval K17"},{"type":"ForeignBrandName","name":"Softenon"},{"type":"ForeignBrandName","name":"Talimol"},{"type":"CASRegistryName","name":"50-35-1"}],"definition":{"html":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","text":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/thalidomide","text":"Thalidomide"},"nciConceptId":"C870","nciConceptName":"Thalidomide","termId":42332,"name":"Thalidomide","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"thalidomide"}],"links":null}